Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „darolutamide“
Suchtreffer
Begriffe & Kennungen
Nubeqa · 4.5 · BCRP, OATP1B1 and OATP1B3 substrates Darolutamide is an inhibitor of breast cancer resistance protein (BCRP) a
Eintrag öffnenNubeqa · 4.5 · CYP3A4 and P-gp inducers Darolutamide is a substrate of CYP3A4 and P-glycoprotein (P-gp). Use of strong and mo
Eintrag öffnenNubeqa · 4.5 · CYP3A4 substrates Darolutamide is a mild inducer of CYP3A4. No clinically relevant drug-drug interaction is ex
Eintrag öffnenNubeqa · 4.5 · CYP3A4, P-gp and BCRP inhibitors Darolutamide is a substrate of CYP3A4, P-gp and breast cancer resistance prot
Eintrag öffnenNubeqa · 4.5 · Docetaxel Administration of darolutamide in combination with docetaxel resulted in no clinically relevant chan
Eintrag öffnenNubeqa · 4.5 · Docetaxel Administration of darolutamide in combination with docetaxel resulted in no clinically relevant chan
Eintrag öffnenNubeqa · 4.5 · Effects of darolutamide on other medicinal products
Eintrag öffnenNubeqa · 4.5 · Effects of other medicinal products on darolutamide
Eintrag öffnenNubeqa · 4.5 · UGT1A9 inhibitors Darolutamide is a substrate of UGT1A9. No clinically relevant drug-drug interaction is expec
Eintrag öffnenNubeqa · 4.8 · For additional safety information when darolutamide is administered in combination, refer to the product infor
Eintrag öffnenNubeqa · 4.8 · Fractures Fractures occurred in 4.1% of patients treated with darolutamide and in 3.2% of patients treated wit
Eintrag öffnenNubeqa · 4.8 · Fractures Fractures occurred in 7.5% of patients treated with darolutamide+docetaxel and in 5.1% of patients t
Eintrag öffnenNubeqa · 4.8 · Table 1: Adverse reactions reported in nmCRPC and mHSPC patients treated with darolutamide in ARAMIS and ARANO
Eintrag öffnenNubeqa · 4.8 · Table 2: Adverse reactions reported in mHSPC patients treated with darolutamide in combination with docetaxel
Eintrag öffnenNubeqa · 4.8 · The adverse reactions observed in patients with nmCRPC or mHSPC treated with darolutamide are listed in Table
Eintrag öffnenNubeqa · 4.8 · The most frequently observed adverse reactions in patients with - nmCRPC or mHSPC receiving darolutamide are f
Eintrag öffnenNubeqa · 4.8 · metastatic hormone-sensitive prostate cancer (mHSPC) - treatment with darolutamide in combination with docetax
Eintrag öffnenOrgovyx · 4.5 · Darolutamide Therapeutic Expected: ↔ Expected: ↔ Darolutamide is a dose for weak inducer of Orgovyx CYP3A4. Ho
Eintrag öffnendarolutamide
Eintrag öffnendarolutamide
Eintrag öffnen